{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-019783","form_type":"8-K","ticker":"JUNS","cik":"0001679628","company_name":"JUPITER NEUROSCIENCES, INC.","filed_at":"2025-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.128821+00:00","generated_at":"2026-05-17T02:11:39.791387+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Jupiter Neurosciences secures up to $20M flexible financing from Yorkville; $4M funded at signing","bullets":["Initial $4M pre-paid advance funded via convertible note with $1.50 fixed conversion price and 7% OID.","Additional $2M pre-paid advance contingent on registration statement and stockholder approval; total $6M pre-paid.","Up to $14M available under SEPA over 24 months subject to conditions; proceeds to fund Phase 2 Parkinson's trial and Nugevia growth.","Yorkville receives 131,909 commitment shares and $25K structuring fee; issuance subject to 19.99% Exchange Cap unless stockholder approval obtained.","Convertible notes bear 8% interest, mature Oct 24, 2026; repayment via cash or advance notices under SEPA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-019783","json":"https://secwatch.observer/filing/0001493152-25-019783.json","markdown":"https://secwatch.observer/filing/0001493152-25-019783.md","text":"https://secwatch.observer/filing/0001493152-25-019783.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/0001493152-25-019783-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:11:39.791387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40b99d4c848826322febe511654064dc4ed33d93","claim":"JUPITER NEUROSCIENCES, INC. incurred convertible notes of $4.0 million with YA II PN, LTD.","evidence_excerpt":"The first Pre-Paid Advance in the amount of $3,720,000 was disbursed to the Company on October 27, 2025, in exchange for the Company’s issuance to Yorkville of a Convertible Note in the principal amount of $4.0 million, which was issued with an “original issue discount” (“OID”) of 7.0% (or $280,000) and is initially convertible into Common Stock at a fixed conversion price of $1.50 per share (subject to adjustment as provided in such Convertible Note) (the “First Convertible Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/0001493152-25-019783-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$4.0 million"},{"label":"Counterparty","value":"YA II PN, LTD"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}